KITE’S YESCARTA® CAR T-CELL THERAPY DEMONSTRATES SIGNIFICANTLY LONGER OVERALL SURVIVAL VERSUS STANDARD OF CARE AS INITIAL TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA.

June 05, 2023 - SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta ® (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population. The late-breaking data are...